Appili Therapeutics Inc. (OTCMKTS:APLIF – Get Free Report) was the target of a significant decrease in short interest during the month of October. As of October 15th, there was short interest totalling 1,900 shares, a decrease of 99.0% from the September 30th total of 198,900 shares. Based on an average daily volume of 232,400 shares, the days-to-cover ratio is presently 0.0 days.
Appili Therapeutics Price Performance
Shares of Appili Therapeutics stock opened at $0.03 on Friday. The firm has a 50 day simple moving average of $0.03 and a 200 day simple moving average of $0.03. Appili Therapeutics has a fifty-two week low of $0.01 and a fifty-two week high of $0.05. The firm has a market cap of $3.29 million, a P/E ratio of -0.90 and a beta of -0.48.
Appili Therapeutics (OTCMKTS:APLIF – Get Free Report) last released its earnings results on Tuesday, August 13th. The company reported ($0.01) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.01).
Appili Therapeutics Company Profile
Appili Therapeutics Inc, a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a taste-masked liquid oral suspension formulation of the antibiotic metronidazole to treat anaerobic bacterial, protozoal, and parasitic infections; ATI-1801, a novel topical formulation of paromomycin in Phase III clinical trials for the treatment of cutaneous leishmaniasis and disfiguring skin infections; and ATI-1701, which is a live-attenuated vaccine in preclinical trials for Francisella tularensis.
See Also
- Five stocks we like better than Appili Therapeutics
- Why Are These Companies Considered Blue Chips?
- Texas Roadhouse Stock Steering for New Highs This Year
- There Are Different Types of Stock To Invest In
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- Short Selling: How to Short a Stock
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
Receive News & Ratings for Appili Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Appili Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.